CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $200.3 million in its first quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.71.

The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $1.75 per share.

The RNA interference drug developer posted revenue of $177.6 million in the period, which also topped Street forecasts. Seven analysts surveyed by Zacks expected $176.9 million.

Alnylam shares have risen 10% since the beginning of the year. The stock has climbed slightly more than 4% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News